Results 21 to 30 of about 526 (127)

Pachychoroid Neovasculopathy Disguising as Age-Related Macular Degeneration Treated by Spironolactone and Anti-VEGF Combination Therapy [PDF]

Case Reports in Ophthalmology, 2021
Nonresponse of neovascular age-related macular degeneration (nAMD) to anti-vascular endothelial growth factor (anti-VEGF) therapy can often be attributed to misdiagnosis, and pathologies mimicking AMD might require different therapeutic concepts.
Leonie F. Keidel, Benedikt Schworm, Siegfried G. Priglinger, Jakob Siedlecki   +3 more
doaj   +2 more sources

Short-term outcomes and choroidal morphological changes following aflibercept therapy in pachychoroid neovasculopathy [PDF]

Scientific Reports
To evaluate the short-term outcomes and choroidal morphological changes after three monthly aflibercept injections for pachychoroid neovasculopathy (PNV).
Jae Hui Kim, Sang Min Park, Soon Il Choi, Dong Ik Kim, Joonhong Sohn, Won Ki Lee   +5 more
doaj   +2 more sources

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy [PDF]

Scientific Reports, 2021
To compare the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical ...
Jihyun Yoon, Wontae Yoon, Seung kwan Na, Jihyun Lee, Chul Gu Kim, Jong Woo Kim, Han Joo Cho   +6 more
doaj   +2 more sources

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy [PDF]

Clinical Ophthalmology, 2021
Takamasa Kinoshita, Junya Mori, Akira Hatanaka, Miho Shimizu, Hiroko Imaizumi Department of Ophthalmology, Sapporo City General Hospital, Sapporo, JapanCorrespondence: Takamasa KinoshitaDepartment of Ophthalmology, Sapporo City General Hospital, 1-1, N ...
Kinoshita T, Mori J, Hatanaka A, Shimizu M, Imaizumi H   +4 more
doaj   +2 more sources

Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-naïve pachychoroid neovasculopathy [PDF]

Scientific Reports
Pachychoroid neovasculopathy (PNV) is characterized by increased choroidal thickness, choroidal hyperpermeability, and fluid accumulation. Given its distinct pathophysiology, PNV requires management with anti-VEGF therapy, as its treatment response ...
Areum Jeong, Frenky Ramiro de Jesus, Seung Chul Baek, Min Sagong   +3 more
doaj   +2 more sources

Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy [PDF]

Scientific Reports
The purpose of this study was to determine the recurrence rate, factors, incidence of polypoidal lesions, and risk factors for developing polypoidal lesions after a reduced dose photodynamic therapy (PDT) for pachychoroid neovasculopathy (PNV) without ...
Koji Tanaka, Hajime Onoe, Keigo Takeshima, Michiteru Kono, Yu Wakatsuki, Akiyuki Kawamura, Ryusaburo Mori, Hiroyuki Nakashizuka   +7 more
doaj   +2 more sources

Characteristics of pachychoroid neovasculopathy. [PDF]

Sci Rep, 2020
AbstractRecently, several research groups have reported a newly recognized clinical entity of choroidal neovascularization, termed pachychoroid neovasculopathy. However, its characteristics have yet to be well described. The purpose of this study was to investigate the clinical and genetic characteristics of pachychoroid neovasculopathy regardless of ...
Tagawa M, Ooto S, Yamashiro K, Tamura H, Oishi A, Miyata M, Hata M, Yoshikawa M, Yoshimura N, Tsujikawa A.   +9 more
europepmc   +4 more sources

Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy. [PDF]

J Clin Med, 2021
Pachychoroid neovasculopathy (PNV) is treated with antivascular endothelial growth factor (VEGF) injection and photodynamic therapy (PDT), but no curative treatment has yet been established. We aimed to clarify the treatment results of a reduced dose of PDT for PNV. The subjects were 27 eyes of 27 patients (male:female = 20:7, mean age 58.9 years). PDT,
Tanaka K, Mori R, Wakatsuki Y, Onoe H, Kawamura A, Nakashizuka H.   +5 more
europepmc   +4 more sources

Scleral Thickness as a Risk Factor for Central Serous Chorioretinopathy and Pachychoroid Neovasculopathy. [PDF]

J Clin Med, 2023
Abstract Background/Objectives. While the exact pathophysiology of pachychoroid disorders remains unclear, scleral changes inducing increased venous outflow resistance are hypothesized to be involved. This work aims to investigate anterior scleral thickness (AST) as a risk factor for central serous chorioretinopathy (CSC) and pachychoroid ...
Keidel LF, Schworm B, Langer J, Luft N, Herold T, Hagenau F, Klaas JE, Priglinger SG, Siedlecki J.   +8 more
europepmc   +3 more sources

Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy. [PDF]

Transl Vis Sci Technol, 2023
To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy.Retrospective analysis of 34 eyes treated with intravitreal brolucizumab.
Carosielli M, Carnevali A, Fallico M, Pirozzi E, Chiosi F, Chronopoulos A, Cucciniello P, Affatato M, Rapino G, dell'Omo R, BROCS study group, BROCS (BROlucizumab for the treatment of Central Serous chorioretinopathy) study group†.   +11 more
europepmc   +4 more sources